Cancer Letters
Volume 231, Issue 1 , Pages 43-48 , 8 January 2006

Oral artemisinin prevents and delays the development of 7,12-dimethylbenz[a]anthracene (DMBA)-induced breast cancer in the rat

Received 30 October 2004 ,Accepted 14 January 2005.

References 

  1. Meshnick SR, Yang YZ, Lima V, Kuypers F, Kamchonwongpaisan S, Yuthavong Y. Iron-dependent free radical generation from the antimalarial agent artemisinin (qinghaosu). Antimicrob. Agent Chemother. 1993;37:1108–1114
  2. Zhang F, Gosser DK, Meshnick SR. Hemin-catalyzed decomposition of artemisinin (qinghaosu). Biochem. Pharmacol. 1992;43:1805–1809
  3. Karin M, Mintz B. Receptor-mediated endocytosis of transferrin in developmentally totipotent mouse teratocarcinoma stem cells. J. Biol. Chem. 1981;256:3245–3252
  4. May WS, Cuatrecasas P. Transferrin receptor: its biological significance. J. Membr. Biol. 1985;88:205–215
  5. Reizenstein P. Iron, free radicals and cancer. Med. Oncol. Tumor Pharmacother. 1991;8:229–233
  6. Raaf HN, Jacobsen DW, Savon S, Green R. Serum transferrin receptor level is not altered in invasive adenocarcinoma of the breast. Am. J. Clin. Pathol. 1993;99:232–237
  7. Shterman N, Kupfer B, Moroz C. Comparison of transferrin receptors, iron content and isoferritin profile in normal and malignant human breast cell lines. Pathobiology. 1991;59:19–25
  8. Castaneda VL, Parmley RT, Saldivar VA, Cheah MS. Childhood undifferentiated leukemia with early erythroid markers and c-myb duplication. Leukemia. 1991;5:142–149
  9. Das-Gupta A, Patil J, Shah VI. Transferrin receptor expression by blast cells in acute lymphoblastic leukemia correlates with white cell count and immunophenotype. Indian J. Med. Res. 1996;104:226–233
  10. Singh NP, Lai H. Artemisinin induces apoptosis in human cancer cells. Anticancer Res. 2004;24:2277–2280
  11. Lai H, Singh NP. Selective cancer cell cytotoxicity from exposure to dihydroartemisinin and holotransferrin. Cancer Lett. 1995;91:41–46
  12. Singh NP, Lai H. Selective toxicity of dehydroartemisinin and holotransferrin on human breast cancer cells. Life Sci. 2001;70:49–56
  13. Kelloff GJ, Boone CW, Steele VE, Crowell JA, Lubet R, Doody LA, et al. Development of breast cancer chemopreventive drugs. J. Cell Biochem. Suppl. 1993;17G:2–13
  14. Mehta RG. Experimental basis for the prevention of breast cancer. Eur. J. Cancer. 2000;36:1275–1282
  15. Seeber RM, Smith JT, Waddell BJ. Plasma leptin-binding activity and hypothalamic leptin receptor expression during pregnancy and lactation in the rat. Biol. Reprod. 2002;66:1762–1767
  16. Whysner J, Wang CX. Hepatocellular iron accumulation and increased cell proliferation in polychlorinated biphenyl-exposed Sprague–Dawley rats and the development of hepatocarcinogenesis. Toxicol. Sci. 2001;62:36–45
  17. Chen X, Ding YW, Yang G, Bondoc F, Lee MJ, Yang CS. Oxidative damage in an esophageal adenocarcinoma model with rats. Carcinogenesis. 2000;21:257–263
  18. Yoshiji H, Nakae D, Mizumoto Y, Horiguchi K, Tamura K, Denda A, et al. Inhibitory effect of dietary iron deficiency on inductions of putative preneoplastic lesions as well as 8-hydroxydeoxyguanosine in DNA and lipid peroxidation in the livers of rats caused by exposure to a choline-deficient l-amino acid defined diet. Carcinogenesis. 1992;13:1227–1233
  19. Park YN, Jung WH, Park C. The effect of deferoxamine on the preneoplastic lesions in the chemically induced hepatocarcinogenesis. Yonsei Med. J. 1994;35:388–395
  20. Yoshiji H, Nakae D, Kinugasa T, Matsuzaki M, Denda A, Tsujii T, et al. Inhibitory effect of dietary iron deficiency on the induction of putative preneoplastic foci in rat liver initiated with diethylnitrosamine and promoted by phenobarbital. Br. J. Cancer. 1991;64:839–842
  21. Chen HH, Zhou HJ, Fang X. Inhibition of human cancer cell line growth and human umbilical vein endothelial cell angiogenesis by artemisinin derivatives in vitro. Pharmacol. Res. 2003;48:231–236
  22. Chen HH, You LL, Li SB. Artesunate reduces chicken chorioallantoic membrane neovascularisation and exhibits antiangiogenic and apoptotic activity on human microvascular dermal endothelial cell. Cancer Lett. 2004;211:163–173
  23. Chen HH, Zhou HJ, Wang WQ, Wu GD. Antimalarial dihydroartemisinin also inhibits angiogenesis. Cancer Chemother. Pharmacol. 2004;53:423–432
  24. Chen HH, Zhou HJ, Wu GD, Lou XE. Inhibitory effects of artesunate on angiogenesis and on expressions of vascular endothelial growth factor and VEGF receptor KDR/flk-1. Pharmacology. 2004;71:1–9
  25. Oh S, Jeong IH, Ahn CM, Shin WS, Lee S. Synthesis and antiangiogenic activity of thioacetal artemisinin derivatives. Bioorg. Med. Chem. 2004;12:3783–3790
  26. Wartenberg M, Wolf S, Budde P, Grunheck F, Acker H, Hescheler J, et al. The antimalaria agent artemisinin exerts antiangiogenic effects in mouse embryonic stem cell-derived embryoid bodies. Lab. Invest. 2003;83:1647–1655
  27. Heffelfinger SC, Gear RB, Schneider J, LaDow K, Yan M, Lu F, et al. TNP-470 inhibits 7,12-dimethylbenz[a]anthracene-induced mammary tumor formation when administered before the formation of carcinoma in situ but is not additive with tamoxifen. Lab. Invest. 2003;83:1001–1011
  28. Heffelfinger SC, Yan M, Gear RB, Schneider J, LaDow K, Warshawsky D. Inhibition of VEGFR2 prevents DMBA-induced mammary tumor formation. Lab. Invest. 2004;84:989–998
  29. Yang SX, Xie SS, Gao HL, Long ZZ. Artemisinin and its derivatives enhance T lymphocyte-mediated immune responses in normal mice and accelerate immunoreconstitution of mice with syngeneic bone marrow transplantation. Clin. Immunol. Immunopathol. 1993;69:143–148
  30. Sun XZ. [Experimental study on the immunosuppressive effects of qinghaosu and its derivative]. Zhong Xi Yi Jie He Za Zhi. 1991;11:37–38
  31. Tawfik AF, Bishop SJ, Ayalp A, El-Feraly FS. Effects of artemisinin, dihydroartemisinin and arteether on immune responses of normal mice. Int. J. Immunopharmacol. 1990;12:385–389
  32. Brewer TG, Genovese RF, Newman DB, Li Q. Factors relating to neurotoxicity of artemisinin antimalarial drugs ‘listening to arteether’. Med. Trop. (Mars). 1998;58(3 Suppl.):22–27
  33. Dhingra V, Rao KV, Narasu ML. Current status of artemisinin and its derivatives as antimalarial drugs. Life Sci. 2000;66:279–300
  34. Li Y, Wu YL. An over four millennium story behind qinghaosu (artemisinin—a fantastic antimalarial drug from a traditional chinese herb). Curr. Med. Chem. 2003;10:2197–2230
  35. Navaratnam V, Mansor SM, Sit NW, Grace J, Li Q, Olliaro P. Pharmacokinetics of artemisinin-type compounds. Clin. Pharmacokinet. 2000;39:255–270
  36. Ribeiro IR, Olliaro P. Safety of artemisinin and its derivatives. A review of published and unpublished clinical trials. Med. Trop. (Mars). 1998;58(3 Suppl.):50–53
  37. Gordi T, Lepist E-I. Artemisinin derivatives: toxic for laboartaory animals, safe for humans?. Toxicol. Lett. 2004;147:99–107
  38. Kohn EC, Liotta LA. Molecular insights into cancer invasion: strategies for prevention and intervention. Cancer Res. 1995;55:1856–1862

PII: S0304-3835(05)00072-8

doi: 10.1016/j.canlet.2005.01.019

Cancer Letters
Volume 231, Issue 1 , Pages 43-48 , 8 January 2006

Article Tools

* Image Usage & Resolution